514 related articles for article (PubMed ID: 15537471)
1. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
2. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.
Vinik AI; Zhang Q
Diabetes Care; 2007 Apr; 30(4):795-800. PubMed ID: 17259481
[TBL] [Abstract][Full Text] [Related]
3. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
4. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
[TBL] [Abstract][Full Text] [Related]
5. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
6. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
[TBL] [Abstract][Full Text] [Related]
7. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
[TBL] [Abstract][Full Text] [Related]
8. Initiation of insulin glargine in children and adolescents with type 1 diabetes.
Tan CY; Wilson DM; Buckingham B
Pediatr Diabetes; 2004 Jun; 5(2):80-6. PubMed ID: 15189493
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
10. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
12. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
Yenigun M; Honka M
Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627
[TBL] [Abstract][Full Text] [Related]
13. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
14. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
[TBL] [Abstract][Full Text] [Related]
15. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
16. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L
Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
[TBL] [Abstract][Full Text] [Related]
17. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
[TBL] [Abstract][Full Text] [Related]
18. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
19. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.
Bradley C; Gilbride CJ
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():50-65. PubMed ID: 18577157
[TBL] [Abstract][Full Text] [Related]
20. Effects of metabolic control, patient education and initiation of insulin therapy on the quality of life of patients with type 2 diabetes mellitus.
Braun A; Sämann A; Kubiak T; Zieschang T; Kloos C; Müller UA; Oster P; Wolf G; Schiel R
Patient Educ Couns; 2008 Oct; 73(1):50-9. PubMed ID: 18583087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
